Opinion|Videos|March 11, 2024
Screening and Diagnosing of Ph+ ALL in Adults
The panel discusses optimal strategies for screening and detecting Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients across different treatment stages.
Advertisement
Episodes in this series
Advertisement
Related to this article
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
4
FDA Approves First At-Home Subcutaneous Thyroid Eye Disease Treatment
5